Ikbel Achour

1.3k total citations
30 papers, 601 citations indexed

About

Ikbel Achour is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Ikbel Achour has authored 30 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 9 papers in Oncology and 8 papers in Immunology. Recurrent topics in Ikbel Achour's work include Bioinformatics and Genomic Networks (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Ikbel Achour is often cited by papers focused on Bioinformatics and Genomic Networks (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Ikbel Achour collaborates with scholars based in United States, France and Spain. Ikbel Achour's co-authors include François Rougeon, Pierre Lafaye, Yves A. Lussier, Vincent Gardeux, Charles Duyckaerts, Haiquan Li, Patrick England, Robert Wuerffel, Amy Kenter and Christiane Bouchier and has published in prestigious journals such as Journal of Clinical Oncology, Genes & Development and Bioinformatics.

In The Last Decade

Ikbel Achour

29 papers receiving 590 citations

Peers

Countries citing papers authored by Ikbel Achour

Since Specialization

Citations

This map shows the geographic impact of Ikbel Achour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ikbel Achour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ikbel Achour more than expected).

Fields of papers citing papers by Ikbel Achour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ikbel Achour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ikbel Achour. The network helps show where Ikbel Achour may publish in the future.

Co-authorship network of co-authors of Ikbel Achour

This figure shows the co-authorship network connecting the top 25 collaborators of Ikbel Achour. A scholar is included among the top collaborators of Ikbel Achour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ikbel Achour. Ikbel Achour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1853MO Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-naïve metastatic non-small cell lung cancer (mNSCLC): ARTEMIDE-01 2025 ·Annals of Oncology ·Byoung Chul Cho, J.T.J.N. Hiltermann, Hiroki Izumi, Mariana Brandão, (unknown), Pongwut Danchaivijitr, Enriqueta Felip, Gwo Fuang Ho, (unknown), Yongsheng Li, (unknown), (unknown), Els Wauters, (unknown), Tatsuya Yoshida, (unknown), Ikbel Achour, (unknown), (unknown), Yulei Wang	0
2	1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01 2023 ·Annals of Oncology ·Mariana Brandão, J.T.J.N. Hiltermann, Els Wauters, Benjamin Solomon, (unknown), Enriqueta Felip, Eelke Gort, Hiroki Izumi, Dongwook Kim, (unknown), Kristoffer Staal Rohrberg, (unknown), Tatsuya Yoshida, (unknown), (unknown), Ikbel Achour, (unknown), Francesca Aroldi, Byoung Chul Cho	6
3	1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC) 2023 ·Annals of Oncology ·Martin H. Voss, Benjamin Garmezy, (unknown), J.P. Maroto Rey, André Mansinho, Alejo Rodríguez‐Vida, Júlio Oliveira, Martien van Dongen, (unknown), Sylvie Négrier, Ben Tran, Benedito A. Carneiro, (unknown), Sun Young Rha, Yan Wang, Shelby D. Gainer, Zhiyuan Tang, Ikbel Achour, (unknown), Laurence Albigès	7
4	LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial 2022 ·Annals of Oncology ·M-J. Ahn, S-W. Kim, Enric Carcereny, Laura Rodríguez, Jorge Oliveira, (unknown), Margarita Majem, Luís Costa, Wu‐Chou Su, K.H. Lee, James Chih‐Hsin Yang, David R. Spigel, (unknown), M. D’Arcangelo, (unknown), Angelo Delmonte, (unknown), Ikbel Achour, Deepa S. Subramaniam, Enriqueta Felip	15
5	Somatic mutations in BRCA2, NFE2L2, ARID1A and NOTCH1 sensitize to anti-PDL1 therapy in multiple tumor types 2018 ·Annals of Oncology ·(unknown), Han Si, Brandon W. Higgs, Philip Z. Brohawn, Katie Streicher, Maria Jure‐Kunkel, Remya Raja, Elena Helman, Aleksandra Franovic, (unknown), Yashaswi Shrestha, (unknown), (unknown), Ikbel Achour, Jiabu Ye, P. Mukhopadhyay, (unknown), Giovanni Melillo, Shaad E. Abdullah, K. Ranade	4
6	53BP1 Contributes to Igh Locus Chromatin Topology during Class Switch Recombination 2017 ·The Journal of Immunology ·Steven R. Feldman, Robert Wuerffel, Ikbel Achour, Lili Wang, Phillip B. Carpenter, Amy Kenter	21
7	N-of-1-pathways MixEnrich: advancing precision medicine via single-subject analysis in discovering dynamic changes of transcriptomes 2017 ·BMC Medical Genomics ·(unknown), (unknown), Vincent Gardeux, Ikbel Achour, (unknown), Joanne Berghout, Haiquan Li, Hao Helen Zhang, Yves A. Lussier	20
8	kMEn: Analyzing noisy and bidirectional transcriptional pathway responses in single subjects 2016 ·Journal of Biomedical Informatics ·(unknown), (unknown), Vincent Gardeux, Joanne Berghout, Ikbel Achour, (unknown), Haiquan Li, Hao Helen Zhang, Yves A. Lussier	10
9	Integrative genomics analyses unveil downstream biological effectors of disease-specific polymorphisms buried in intergenic regions 2016 ·npj Genomic Medicine ·Haiquan Li, Ikbel Achour, Lisa Bastarache, Joanne Berghout, Vincent Gardeux, Jianrong Li, Younghee Lee, Lorenzo L. Pesce, Xinan Yang, Kenneth S. Ramos, Ian Foster, Joshua C. Denny, Jason H. Moore, Yves A. Lussier	16
10	Analysis of aggregated cell–cell statistical distances within pathways unveils therapeutic-resistance mechanisms in circulating tumor cells 2016 ·Bioinformatics ·(unknown), (unknown), James L. Chen, (unknown), Ikbel Achour, Dean Billheimer, Haiquan Li, Walter W. Piegorsch, Yves A. Lussier	12
11	Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform 2015 ·mAbs ·A. Klarenbeek, (unknown), Aline Desmyter, Christophe Blanchetot, Anna Hultberg, Natalie De Jonge, Rob C. Roovers, Christian Cambillau, (unknown), Jurgen Del‐Favero, Theo Verrips, Hans J. de Haard, Ikbel Achour	74
12	eQTL networks unveil enriched mRNA master integrators downstream of complex disease-associated SNPs 2015 ·Journal of Biomedical Informatics ·Haiquan Li, Nima Pouladi, Ikbel Achour, Vincent Gardeux, Jiànróng Lǐ, (unknown), Hao Helen Zhang, Fernando D. Martínez, Joe G. N. Garcia, Yves A. Lussier	8
13	‘N-of-1-pathways’ unveils personal deregulated mechanisms from a single pair of RNA-Seq samples: towards precision medicine 2014 ·Journal of the American Medical Informatics Association ·Vincent Gardeux, Ikbel Achour, Jianrong Li, Mark Maienschein‐Cline, Haiquan Li, Lorenzo L. Pesce, (unknown), Neil Bahroos, Robert A. Winn, Ian Foster, Joe G. N. Garcia, Yves A. Lussier	32
14	In Silicocancer cell versus stroma cellularity index computed from species-specific human and mouse transcriptome of xenograft models: towards accurate stroma targeting therapy assessment 2014 ·BMC Medical Genomics ·Xinan Yang, Yong Huang, Younghee Lee, Vincent Gardeux, Ikbel Achour, Kelly Regan, (unknown), Haiquan Li, Yves A. Lussier	2
15	The discriminatory cost of ICD-10-CM transition between clinical specialties: metrics, case study, and mitigating tools 2013 ·Journal of the American Medical Informatics Association ·Andrew D. Boyd, (unknown), (unknown), (unknown), Vincent Gardeux, Ikbel Achour, (unknown), (unknown), Neil Bahroos, Stephen B. R. E. Brown, Terry L. Vanden Hoek, Yves A. Lussier	49
16	Flexible ordering of antibody class switch and V(D)J joining during B-cell ontogeny 2013 ·Genes & Development ·(unknown), Robert Wuerffel, Ikbel Achour, Bryan R. Lajoie, Ranjan Sen, Job Dekker, Ann J. Feeney, Amy Kenter	33
17	Network models of genome-wide association studies uncover the topological centrality of protein interactions in complex diseases 2013 ·Journal of the American Medical Informatics Association ·Younghee Lee, Haiquan Li, Jianrong Li, (unknown), Ikbel Achour, Kelly Regan, Eric R. Gamazon, James L. Chen, Xinan Yang, Nancy J. Cox, Yves A. Lussier	33
18	Three‐dimensional architecture of the IgH locus facilitates class switch recombination 2012 ·Annals of the New York Academy of Sciences ·Amy Kenter, Steven R. Feldman, Robert Wuerffel, Ikbel Achour, Lili Wang, (unknown)	20
19	Single-domain antibodies recognize selectively small oligomeric forms of amyloid β, prevent Aβ-induced neurotoxicity and inhibit fibril formation 2008 ·Molecular Immunology ·Pierre Lafaye, Ikbel Achour, Patrick England, Charles Duyckaerts, François Rougeon	84
20	Tetrameric and Homodimeric Camelid IgGs Originate from the Same IgH Locus 2008 ·The Journal of Immunology ·Ikbel Achour, Patricia Cavelier, (unknown), Christiane Bouchier, Pierre Lafaye, François Rougeon	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact